Home › Companies › TVTX

Pipeline (7 active programs)

Biotech Distilled coverage (11)

• 2026-08-05 UPDATE: Travere Therapeutics (TVTX) - The Blowout Quarter, and Two Things Buried in the 10-Q 🔒 Paid
• 2026-06-04 UPDATE: Travere Therapeutics (TVTX) - The DUPLEX Switch-Arm Data Answers the Question That Haunted the FSGS PDUFA
• 2026-06-02 UPDATE: Travere Therapeutics (TVTX) - The $112.5M Answer to the “What’s the Cash For” Question
• 2026-05-27 UPDATE: Travere Therapeutics (TVTX) - The 2030 Patent Cliff Just Got Pushed to 2037 🔒 Paid
• 2026-05-08 UPDATE: Travere Therapeutics (TVTX) - The Convert Math Prints, And It’s Better Than I Modeled 🔒 Paid
• 2026-05-06 UPDATE: Travere Therapeutics (TVTX) - The $400M Convert Refi Lands One Day After the Q1 Print 🔒 Paid
• 2026-05-04 UPDATE: Travere Therapeutics (TVTX) - The Profitability Inflection Arrives
• 2026-04-18 UPDATE: Travere Therapeutics (TVTX) - The FDA Folds, The Bulls Win, and FILSPARI Gets the FSGS Crown 🔒 Paid
• 2026-04-04 UPDATE: Travere Therapeutics (TVTX) - The C-Suite is Selling 12 Days Before the FDA Verdict 🔒 Paid
• 2026-02-21 UPDATE: Travere Therapeutics (TVTX) - Commercial Liftoff, CMC Recovery, and Why the Smart Money is Trimming 🔒 Paid
• 2026-02-06 Travere Therapeutics (TVTX): Scientific Deep Dive for Sparsentan, Pegtibatinase, and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.